[go: up one dir, main page]

MX2013010945A - Sintesis de 5 - azacitidina. - Google Patents

Sintesis de 5 - azacitidina.

Info

Publication number
MX2013010945A
MX2013010945A MX2013010945A MX2013010945A MX2013010945A MX 2013010945 A MX2013010945 A MX 2013010945A MX 2013010945 A MX2013010945 A MX 2013010945A MX 2013010945 A MX2013010945 A MX 2013010945A MX 2013010945 A MX2013010945 A MX 2013010945A
Authority
MX
Mexico
Prior art keywords
azacytidine
systhesis
disorders
mds
treating
Prior art date
Application number
MX2013010945A
Other languages
English (en)
Inventor
Chinnapillai Rajendiran
Periyandi Nagarajan
Jasti Venkateswarlau
Original Assignee
Celgene Internat Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Internat Sarl filed Critical Celgene Internat Sarl
Publication of MX2013010945A publication Critical patent/MX2013010945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan los procesos para la preparación de 5-azacitidina, útiles para tratar, prevenir y/o manejar enfermedades o trastornos como cáncer, trastornos relacionados con la proliferación celular anormal, trastornos hematológicos y síndromes mielodisplásicos (MDS), en donde la 5-azacitidina está representada por la estructura: (ver Fórmula).
MX2013010945A 2011-03-31 2012-03-29 Sintesis de 5 - azacitidina. MX2013010945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470392P 2011-03-31 2011-03-31
PCT/US2012/031059 WO2012135405A1 (en) 2011-03-31 2012-03-29 Systhesis of 5-azacytidine

Publications (1)

Publication Number Publication Date
MX2013010945A true MX2013010945A (es) 2014-03-12

Family

ID=46000343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010945A MX2013010945A (es) 2011-03-31 2012-03-29 Sintesis de 5 - azacitidina.

Country Status (13)

Country Link
US (1) US9951098B2 (es)
EP (1) EP2691408B1 (es)
JP (1) JP6289361B2 (es)
KR (1) KR20140019820A (es)
CN (1) CN103619864A (es)
AU (1) AU2012236476A1 (es)
BR (1) BR112013025167A2 (es)
IL (1) IL228604A0 (es)
MX (1) MX2013010945A (es)
RU (1) RU2013148580A (es)
SG (1) SG193622A1 (es)
WO (1) WO2012135405A1 (es)
ZA (1) ZA201307142B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
US10370415B2 (en) 2013-04-11 2019-08-06 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
US10221216B2 (en) 2013-04-11 2019-03-05 Carnegie Mellon University Template-directed γPNA synthesis process and γPNA targeting compounds
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
CN104672289A (zh) * 2013-11-29 2015-06-03 南京圣和药业股份有限公司 一种阿扎胞苷杂质的制备方法
WO2017183215A1 (ja) * 2016-04-21 2017-10-26 大原薬品工業株式会社 ５－アザシチジン類の糖部シリルエーテル誘導体
CN109923105A (zh) * 2016-09-26 2019-06-21 卡耐基梅隆大学 二价核碱基化合物及其用途
CN109305992A (zh) * 2017-07-28 2019-02-05 江苏先声药业有限公司 一种阿扎胞苷的制备方法
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CN110092807A (zh) * 2018-01-30 2019-08-06 中国医学科学院药物研究所 一种高纯、低灼烧残渣的制备阿扎胞苷的方法
CA3090291C (en) 2018-02-07 2023-10-17 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
KR20190136284A (ko) * 2018-05-30 2019-12-10 주식회사 삼양바이오팜 안정한 아자시티딘-함유 약제학적 조성물의 제조방법
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
JP2023524522A (ja) 2020-05-01 2023-06-12 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ｃｏｖｉｄ－１９剤としてのｅタンパク質チャネル遮断薬およびｏｒｆ３阻害剤
CN113201039B (zh) * 2021-05-19 2022-04-29 南京德克瑞医药化工有限公司 一种医药中间体2’,3’,5’-三乙酰阿扎胞苷的制备方法
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (es) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
ATE238328T1 (de) 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
CA2499036A1 (en) 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
WO2005023179A2 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
EP2644614A3 (en) 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Solid state forms of 5-azacytidine and processes for preparation thereof
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
KR20110026019A (ko) 2008-08-06 2011-03-14 시코르, 인크. 아자시티딘 중간체의 제조 방법
CN102216315B (zh) * 2008-08-08 2016-06-29 台湾神隆股份有限公司 制备5-氮杂胞嘧啶核苷和其衍生物的方法
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
ZA201307142B (en) 2015-11-25
US9951098B2 (en) 2018-04-24
IL228604A0 (en) 2013-12-31
JP2014510755A (ja) 2014-05-01
RU2013148580A (ru) 2015-05-10
WO2012135405A1 (en) 2012-10-04
AU2012236476A1 (en) 2013-05-02
CN103619864A (zh) 2014-03-05
SG193622A1 (en) 2013-11-29
KR20140019820A (ko) 2014-02-17
BR112013025167A2 (pt) 2019-09-24
US20140128593A1 (en) 2014-05-08
JP6289361B2 (ja) 2018-03-07
EP2691408B1 (en) 2017-06-28
EP2691408A1 (en) 2014-02-05

Similar Documents

Publication Publication Date Title
MX2013010945A (es) Sintesis de 5 - azacitidina.
CA2871471C (en) Dna-pk inhibitors
MX343561B (es) Compuestos de imidazolpiridazina.
WO2013003112A9 (en) Methods and compositions for treatment of cancer and autoimmune disease
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
PH12015502839B1 (en) Antiviral compounds
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
IN2015DN01156A (es)
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EP3792280A3 (en) Anti-blys antibody
IN2014DN09134A (es)
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
IN2012DN02081A (es)
MX352928B (es) Compuestos de piridazina-amida.
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
MX342310B (es) Compuestos de tiazolopirimidina.
MX2015006124A (es) Inhibidores del contransportador 1 de sodio glucosa.
IN2015DN01119A (es)
IN2014DN06104A (es)
IL216084A0 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
WO2012167028A9 (en) Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
MX349548B (es) Compuestos de tienopirimidina.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
PH12013500831A1 (en) Oxazoline and isoxazoline derivatives as crac modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal